Venus Remedies FY26 AGM Approves 100% Dividend, 127% PAT Surge

Date: August 20, 2026 at 11:30 AM IST through Video Conferencing
Cut-off date for voting: August 13, 2026
Record date for dividend: August 7, 2026
Remote e-voting period: August 17-19, 2026 through MUFG Intime India Private Ltd.
Scrutinizer: Mr. Prince Chadha of M/s P. Chadha & Associates

Revenue from operations: ₹768.73 Crore (vs ₹644.47 Crore in FY25)
Profit Before Tax: ₹130.67 Crore (vs ₹79.08 Crore in FY25)
Profit After Tax: ₹99.31 Crore (89% growth vs ₹52.56 Crore in FY25)
Earnings Per Share: ₹74.29 (vs ₹39.32 in FY25)
Total assets: ₹876.06 crore (vs ₹713.21 crore in FY25)

Zero Debt Position: Maintained for third consecutive year
Cash & Investments: Exceed ₹250 Crore on balance sheet
Capital Work-in-Progress: Doubled to ₹51.36 Crore indicating ongoing capacity expansion
Dividend: Recommended final dividend of ₹10 per share (100% on face value) - first payout in over a decade

Mr. Pawan Chaudhary (Chairman & MD), Dr. Manu Chaudhary (Joint MD), Mr. Peeyush Jain (Deputy MD)
Mr. Ashutosh Jain (Executive Director), Mr. Akshansh Chaudhary (Executive Director)
Five Independent Directors including Dr. Savita Gupta and Mr. NPS Monga

1. Adoption of audited standalone and consolidated financial statements

2. Declaration of final dividend of ₹10 per equity share

3. Re-appointment of Mr. Ashutosh Jain and Mr. Peeyush Jain as Directors

4. Ratification of cost auditor remuneration for FY 2026-27

5. Appointment of Saransh Chaudhary as Executive Director for 5 years

6. Appointment of Dr. Gurminder Singh as Non-Executive Independent Director

7. Re-appointment of Dr. Manu Chaudhary as Joint Managing Director for 5 years

8. Re-appointment of Dr. Savita Gupta as Non-Executive Independent Director

9. Comprehensive revision and modernization of Memorandum of Association

10. Adoption of revised Articles of Association

Manufacturing Output: Achieved record production of 1+ Crore units in a single month
International Presence: Operations across 100+ countries with 90 first market-authorization grants
Regulatory Compliance: Cleared 5 international audits
R&D Pipeline: 9 products across 6 therapy areas with 150+ patents granted globally
Plant Locations: Panchkula (Haryana) and Baddi (Himachal Pradesh)

Venus Pharma GmbH (Germany): Total assets ₹24.95 crore, Revenue ₹26.84 crore, Net profit ₹3.48 crore
Venus Pharma Kft (Hungary): Total assets ₹0.08 crore
Sunev Pharma Solutions Private Limited: Mentioned as related entity

CSR Expenditure: ₹128.18 lakhs spent against requirement of ₹104.10 lakhs
Activities: Healthcare, education, environment sustainability, women empowerment
Compliance Certificates: Corporate Governance, Non-disqualification of Directors, Unqualified audit opinions
Auditors: J.K. Jain & Associates (Statutory), P. Chadha & Associates (Secretarial), C.L. Bansal & Associates (Cost)